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ABSTRACT
Cancer researchers are currently embarking on one of their field’s biggest 
challenges, namely the understanding of how cellular metabolism or certain 
classes of elite metabolites (e.g., oncometabolites) can directly influence chromatin 
structure and the functioning of epi-transcriptional circuits to causally drive tumour 
formation. We here propose that refining the inherent cell attractor nature of nuclear 
reprogramming phenomena by adding the under-appreciated capacity of metabolism 
to naturally reshape the Waddingtonian landscape’s topography provides a new 
integrative metabolo-epigenetic model of the cancer stem cell (CSC) theory. 
By emphatically underscoring the similarities 
in nuclear reprogramming pathways involved in the 
generation of induced pluripotent stem cells (iPSCs) 
and cancer stem cells (CSCs), one of the conclusions 
drawn from the 2013 Nature-Ludwig Institute for Cancer 
Research Conference on “Nuclear Reprogramming and 
the Cancer Genome” has been to suggest a new cancer 
hallmark, namely mutations or expression changes in 
metabolic genes that are implicated in the regulation of 
DNA methylation plasticity [1]. 
Oncometabolites and the stem cell origin of 
cancers: A Darwinian view
In cancers with a stem cell origin such as 
haematopoietic malignancies, gain-of-function 
isocitrate dehydrogenases (IDH) mutations generating 
the oncometabolite 2-hydroxyglutarate (2HG) lead to 
global hypermethylation [2]. This activity prevents 
the demethylation of genes that are implicated in 
differentiation, consequently promoting a stabilization 
of undifferentiated and self-renewing cellular states that 
may be targetable and expanded by later transforming 
mutations. For most solid tumours with non-stem cell 
origins, including liver, breast, lung, pancreatic and 
prostate cancer, in which mutations in metabolic genes are 
not widespread, it was alternatively proposed that an intact 
metabolic function of IDH would be necessary to maintain 
DNA methylation plasticity and a flexible epigenetic 
landscape [1]. 
The latter proposal, however, can be somewhat 
difficult to reconcile with the actual functioning of the 
oncometabolite 2HG in solid tumours such as intrahepatic 
cholangiocarcinomas (IHCCs) [3] and breast carcinomas 
(BCs) [4]. IHCC is a deadly liver malignancy in which 
highly prevalent 2HG-producing IDH mutations subvert 
the hepatocyte differentiation/quiescence program to 
create a persistent pre-neoplastic state, which is primed 
for transformation into adenocarcinoma by additional 
oncogenic mutations [3]. In the absence of IDH mutations, 
the accumulation of 2HG is part of the c-Myc-driven 
metabolic reprogramming observed in biologically 
aggressive BCs that exhibit globally increased DNA 
methylation [4]. The hypermethylation phenotype of 2HG-
overexpressing IHCC and BC is characterised by a strong 
enrichment of a stem cell-like transcriptional signature [3, 
4]. Why do oncometabolic traits convergently “encode” an 
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Figure 1: A Waddingtonian perspective of the metabolo-epigenetic reprogramming of stemness in cancer tissues. A. A 
highly active crosstalk process between certain metabotypic features, elite metabolites (e.g., oncometabolites), and epigenetics could allow 
the causal integration of the metabolism with genetic programs to generate CSC functions via pathological nuclear reprogramming [1, 9]. 
The acquisition of stemness in cancer tissues might not only be hard-wired by the mutational landscape but also by the pivotal regulatory 
role of the cellular metabotype. This relationship, in turn, can remove, diminish, or modify the nature of the molecular barriers present in 
Waddington’s epigenetic landscapes, thus allowing cells to more easily (re-)enter into CSC cellular macrostates. In this metabostemness 
framework, even modest changes in the “protected” versus “permissive” nature of the cellular metabotype are expected to produce a 
considerable change in the global kinetic efficiency of the CSC reprogramming process. The cellular metabotype can be described by means 
of variability criteria, such as the presence or absence of particular metabolites (e.g., oncometabolites such as 2HG), the concentration 
levels of certain metabolites, the relative levels or ratios between specific metabolites, metabolic profiles or even spatio-temporal flux 
distributions of metabolites (e.g., N-acetylglucosamine [GlcNAc] for histone GlcNAcylation, the NAD+/NADH ratio for sirtuin histone 
deacetylase activities, acetyl-CoA as a donor for histone acetylation, alpha-ketoglutarate as a cofactor for histone and DNA demethylation 
reactions, S-adenosylmethionine [SAM] as a donor for DNA methylation, or ATP/AMP-regulated chromatin translocation of AMPK for 
histone phosphorylation). B. The cellular metabotype may act as “starter dough” that renders any type of cell-of-origin susceptible to the 
epigenetic rewiring required for the acquisition of refractoriness to differentiation [9]. This modification can significantly alter the efficiency 
and speed of CSC reprogramming in cancers with (top) and without (bottom) a stem cell origin by lowering the barriers of the epigenetic 
landscape and increasing the size of the basins of attraction, which are necessarily located in the developmentally immature, stem-like 
regions of the “higher mountains” of the landscape. From a therapeutic perspective, small perturbations in a particular metabolic pathway 
or metabolite might have drastic consequences on the formation, maintenance, and evolution of CSC cellular states. Indeed, the unexpected 
applications for biguanides in oncology might closely relate to their metabolic effects during the induction of CSCs [15-17]. (OGT: O-linked 
N-acetylglucosamine transferase; SIRT1/6: NAD+-dependent SIRTUIN histone deacetylases (HDACs); HAT: Histone acetyltransferases; 
JHDM/TET: Jumonji-C domain containing histone demethylases (HDMs)/Ten-eleven translocation (Tet) methylcytosine dioxygenases; 
HMT/DNMT: Histone methyltransferase/DNA methyltransferases)
Oncoscience805www.impactjournals.com/oncoscience
immature, stem-like program in cancer tissue, regardless 
of the stem cell/non-stem cell source? 
It has been argued that the cell-of-origin dictates 
the metaboloepigenetic relationship between nuclear 
reprogramming and the generation of CSCs [1], an ad hoc 
evolutionary assumption in which natural forces might 
select for either “hierarchic” or “dynamic” epigenetic 
landscapes depending on their stem cell or non-stem cell 
origin, respectively. Instead, we here propose that refining 
the inherent cell attractor nature of nuclear reprogramming 
phenomena [5-8] by adding the under-appreciated capacity 
of metabolism to naturally reshape the Waddingtonian 
landscape’s topography provides a new integrative 
perspective of the CSC theory that is free of any ad hoc 
argumentation. 
Metaboloepigenetic reprogramming of cancer 
stem cells: A Waddingtonian view
We recently coined the term “metabostemness” to 
refer to the metabolic parameters causally controlling 
or functionally substituting the epi-transcriptional 
orchestration of CSC nuclear reprogramming [9]. A central 
metabostemness element is the metabolo-epitranscriptional 
switcher, which decodes the metabolism’s ability 
to interfere with the developmental Waddington’s 
“buffering” and “canalization” via the removal, lowering 
or modification of landscape “energy” barriers (Fig. 1A). 
Two key operational features determine the functioning of 
metabostemness: a.) Two primary epigenetic codes, DNA 
methylation and histone modification, and the consequent 
epigenetic regulation of cell differentiation genes are the 
pivotal molecular events that account for the regulatory 
effects of metabolism on nuclear reprogramming [10], 
and b.) the switcher is responsive not only to bona fide 
oncometabolites but also to more common primary 
metabolites employed by chromatin-remodelling 
enzymes [9, 10], implying that even small changes in the 
landscape’s fine topography (e.g., metabolically driven 
leaning of a slope in a separating barrier) could sufficiently 
place cells into the basins of CSC attractors without the 
intervention of mutational events. In cancers with a stem 
cell origin, certain metabotypes might provoke cells to get 
stuck very near or in the same state-space of attractors of 
previously normal stem cells (e.g., by increasing the size 
of the basins and, therefore, the resilience of stem-like 
states), which will subsequently increase the probability 
of undifferentiated cells targetable by pro-proliferative 
oncomutations (Fig. 1B, top). For cancers with non-
stem cell origins, certain metabotypes can permissively 
alleviate the “uphill”, unfavourable developmental process 
of “jumping back” from non-CSC differentiated valleys 
to high-altitude CSC attractors while concomitantly 
promoting the ground-state character of self-maintaining 
CSC-like states (Fig. 1B, bottom). 
Cell types can occupy attractors even after the 
metabolic stimulus triggering the transition disappears, 
a “memory effect” in a multi-attractor, flexible landscape 
that explains why the transient occurrence of CSC-
promoting events (e.g., hypoxia- or acidic pH-induced 
loss of pro-differentiation factors) [11, 12] are sufficient 
to generate a lasting CSC population (e.g., long-lived 
dormant stem cell-like cells). If certain metabotypes confer 
a proliferative advantage on cells trapped in abnormal 
attractors, somatic evolution can further deepen them and, 
therefore, promote their over-occupancy by specific cancer 
cell types (e.g., IDH-mutated IHCC with stem cell features 
and exhibiting bile duct differentiation) [3]. 
CONCLUSIONS
CSC states can be viewed as inherently inevitable 
epigenetic deviations of Waddington’s developmental 
landscapes in which metabolism modifies the probability 
that not only stem cells/early progenitors but also normal 
or tumour-differentiated cells can find either pre-existing 
or de novo occupied, self-organising attractors encoding 
dynamically robust CSC signatures that somatic evolution 
alone cannot explain. Oncometabolites can therefore 
operate as the metabolic basis for the epigenetic landscape 
of tumour-initiating events regardless of the stem cell/non-
stem cell source and without the requirement of mutations 
in metabolic enzymes [13, 14].
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